Skip to main content
S&P 5007,720.39-0.30%DOW52,342.56-0.25%NASDAQ26,184.72-1.38%BTC$77,045.00-4.95%ETH$2,215.83-5.85%GOLD$4,026.60-0.12%OIL$102.79+0.77%
Smart Investors Daily
SID Premium
AI

NASDAQ · AIMD

Ainos, Inc.

Healthcare · Biotechnology

$0.73

Down-$0.08 (-10.09%)

Updated Oct 30, 2026, 7:31 AM

SID Score

2.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.91M
P/E ratio
-0.5
Dividend yield
0.00%
52-week range
$0.68 – $3.88
Volume
60.64K
Avg. volume
660.22K

Price performance · AIMD

AIMD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

AIMD closed at $0.73 after 21 trading sessions, down 43.92% for the selected period.

Last close
$0.73
Period change
-43.92%
Period low
$0.73
Period high
$1.35
Daily close
View OHLC price history
AIMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$0.82$0.82$0.6811$0.72960.64K
Oct 28, 2026$0.82$0.82$0.7849$0.81094.27K
Oct 27, 2026$0.81$0.8565$0.7801$0.79465.33K
Oct 26, 2026$0.80$0.8779$0.7825$0.782517.4K
Oct 23, 2026$0.844$0.8689$0.785$0.837228.4K
Oct 22, 2026$0.9244$0.968$0.8441$0.844132.36K
Oct 21, 2026$0.9899$0.99$0.8801$0.880121.01K
Oct 20, 2026$0.90$0.9311$0.89$0.900310.2K
Oct 19, 2026$0.93$0.99$0.80$0.931573.99K
Oct 16, 2026$0.97$1.0525$0.9238$0.923815.67K
Oct 15, 2026$0.93$1.03$0.8702$0.9668.99K
Oct 14, 2026$1.09$1.09$0.9553$0.9636.89K
Oct 13, 2026$1.12$1.12$1.08$1.0832.26K
Oct 12, 2026$1.21$1.21$1.10$1.1446.68K
Oct 9, 2026$1.20$1.2597$1.20$1.2117.61K
Oct 8, 2026$1.24$1.28$1.1717$1.2162K
Oct 7, 2026$1.26$1.28$1.22$1.236140.38K
Oct 6, 2026$1.34$1.3431$1.29$1.2945.02K
Oct 5, 2026$1.349$1.37$1.3117$1.3330.3K
Oct 2, 2026$1.33$1.40$1.33$1.35351.19K
Oct 1, 2026$1.27$1.3599$1.2603$1.3041.9K

Latest AIMD news

The latest Smart Investors Daily articles mentioning AIMD.

Stock researchCompany · Overview

AIMD research

Overview

Company profile and research snapshot.

Company profile

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment

Partner's Written Confirmation Fulfills Payment Conditions; Initial License Fee Payable Within 15 Business DaysHOUSTON, TX / ACCESS Newswire / September 30, 2026 / (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed the required data delivery and technology transfer under its VELDONA® license agreement, triggering a $600,000 initial license payment. The licensing partner confirmed completion in writing on September 29.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By